Autoassembling peptides for the treatment of pulmonary bulla
US-10245299-B2 · Apr 2, 2019 · US
US10793307B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10793307-B2 |
| Application number | US-201314413156-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 3, 2013 |
| Priority date | Jul 6, 2012 |
| Publication date | Oct 6, 2020 |
| Grant date | Oct 6, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The enclosed disclosure describes, among other things, a method including the steps of a first deaerating step in which a mixture comprising peptides is deaerated by lowering the pressure, filtering the mixture through a sterilizing filter; and a second deaerating step, in which the filtrate is deaerated by vibration and lowering the pressure.
Opening claim text (preview).
The invention claimed is: 1. A method comprising: (a) a first deaerating step wherein an aqueous liquid composition of self-assembling peptides having an amino acid sequence of RADARADARADARADA (SEQ ID NO: 1)(“RADA16 peptides”) present at a concentration of at least 0.5 weight % is deaerated by lowering the pressure at a rate of less than about 0.01 MPa/min, (b) a sterilizing step wherein the aqueous liquid composition is passed through a sterilizing filter producing an aqueous liquid filtrate, and wherein the sterilizing step is performed at a pressure of about 0.5 MPa; and (c) a second deaerating step, wherein the aqueous liquid filtrate is deaerated by vibration and lowering the pressure. 2. The method of claim 1 , wherein the sterilizing filter has an average pore size equal or less than about 0.22 μm. 3. The method of claim 1 , wherein the first deaerating step and/or the second deaerating step comprises lowering the pressure by about at least 0.095 MPa. 4. The method of claim 3 , wherein the first deaerating step comprises lowering the pressure by applying a vacuum that is maintained for at least about 30 minutes. 5. The method of claim 1 , wherein the second dea.erating step comprises vibrating the aqueous liquid filtrate at 150 revolutions per minute and an eccentric distance of a vibration motion is between −10 cm and 10 cm. 6. The method of claim 1 , further comprising a step of forming the aqueous liquid composition by mixing the self-assembling peptides with a solvent before the first deaerating step. 7. The method of claim 6 , wherein the solvent is water. 8. The method of claim 1 , further comprising a filling step, wherein the filling step comprising aseptically filling articles with the aqueous liquid composition after the second deaerating step. 9. The method of claim 8 , wherein the articles are filled at least 5 hours after the second deaerating step. 10. The method of claim 8 , wherein the articles are selected from the group consisting of syringes, pouches, vials, tubes, and combinations thereof. 11. The method of claim 8 , further comprising a step of packaging the filled articles with gas permeable materials and a gas sterilization step after the filling step. 12. The method of claim 11 , wherein the gas sterilization step is performed with ethylene oxide gas or hydrogen peroxide gas. 13. The method of claim 11 , wherein the step of packaging the articles is performed with single or double packaging. 14. The method of claim 1 , wherein the sterilizing step is performed at about ambient temperature. 15. The method of claim 1 , wherein the sterilizing filter is constructed from a material selected from the group consisting of the following: cellulose nitrate, cellulose acetate, vinyl polymers, fluorocarbons, polyethylene, ultrahigh molecular weight polyethylene, polypropylene, EVA copolymers and alpha olefins, metallocene olefinic polymers, PFA, MFA, PTFE, polycarbonates, vinyl copolymers, polyamides, nylon, polyesters, cellulose, cellulose acetate, regenerated cellulose, cellulose composites, polysulfone, polyethersulfone, polyarylsulfone, polyphenylsulfone, polyacrylonitrile, polyvinylidene fluoride (PVDF), and blends thereof. 16. The method of claim 1 , wherein the sterilizing filter is constructed from polyethersulfone. 17. The method of claim 1 , wherein the sterilizing step comprises a step of filling the sterilizing filter at a first pressure, then increasing the pressure to pass the aqueous liquid composition through the sterilizing filter. 18. The method of claim 1 , further comprising a step, prior to the step of sterilizing, of washing the sterilizing filter prior to an integrity test. 19. The method of claim 18 , wherein the washing is with water. 20. The method of claim 1 , wherein the sterilizing step is performed in two sterilizing filters operated in parallel. 21. The method of claim 1 , further comprising a cleaning step, which comprises adding steam to filtration and deaeration equipment. 22. The method of claim 1 , wherein the aqueous liquid composition is an aqueous solution. 23. The method of claim 1 , wherein the aqueous liquid composition contains at least 1% weight to volume of the self-assembling peptides. 24. The method of claim 1 , wherein the aqueous liquid composition is an aqueous solution, the aqueous liquid composition contains at least 1% weight to volume of the assembling peptides, and the first d.eaerating step comprises lowering the pressure of the aqueous self-liquid composition at a rate of less than about 0.01 MPa/min.
by filtration, ultrafiltration or reverse osmosis · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
by a combination of two or more processes of different types · CPC title
the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.